Pyrimidine nucleoside phosphorylase and dihydropyrimidine dihydrogenase activities as predictive factors for the efficacy of doxifluridine together with mitomycin C as adjuvant chemotherapy in primary colorectal cancer

Hepato-Gastroenterology

Volumn 54, Issue 76, 2007, Pages 1089-1093

  Nishioka, Masanori ^a   Miyamoto, Hidenori ^a   Kurita, Nobuhiro ^a   Higashijima, Jun ^a   Yoshikawa, Kouzou ^a   Miyatani, Tomohiko ^a   Shimada, Mitsuo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

5 DFUR; Adjuvant chemotherapy; Colorectal cancer; DPD; PyNPase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DOXIFLURIDINE; MITOMYCIN C; PYRIMIDINE NUCLEOSIDE PHOSPHORYLASE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLOXURIDINE; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; PENTOSYLTRANSFERASES; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34347353388     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Kato T, Ohashi Y, Nakazato H, Koike A, Saji S, Suzuki H, Takagi H, Nimura Y, Hasumi A, Baba S, Manabe T, Maruta M, Miura K, Yamaguchi A: Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial. Langenbecks Arch Surg 2002; 386:575-581.
2. Sakamoto J, Hamada C, Kodaira S, Nakazato H, Ohashi Y: Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials. Jpn J Clin Oncol 1999; 29:78-86.
3. Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y, Ishitsuka H: Activation of 5′-deoxy-5-fluororidine by thymidine phosphorylase in human tumors. Chem Pharm Bull 1983; 31:175-178.
4. Hiroyasu S, Shiraishi M, Samura H, Tokashiki H, Shimoji H, Isa T, Muto Yoshihiro: Clinical relevance of the concentrations of both pyrimidine nuculeoside phosphorylase (PyNPase) and dihydropyrimidine dehydrogenase (DPD) in colorectal cancer. Jpn J Clin Oncol 2001; 31:65-68.
5. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4:1013-1019.
6. Folkman J: What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6.
7. Folkman J, Klagsburun M: Angiogenic factor. Science 1987; 235:442-447.
8. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res 1998; 4:1013-1019.
9. Takebayashi Y, Akiyama S, Akiba S, Yamada K, Miyadera K, Sumizawa T, et al: Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88: 1110-1117. 1996;
10. Lu ZH, Zhang R, Diasio RB: Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 1992; 267:17102-17109.
11. Diasio RB, Harris B: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16:215-237.
12. Japanese Research Society for Cancer of Colon and Rectum: General rules for clinical and pathological studies on cancer of the colon, rectum and anus. 4th Edition. Japan: Kanehara&Co, 1985. (In Japanese)
13. Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T, Ishitsuka H: Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 1996; 19:1407-1411.
14. Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa-YS Chung K, Ikeda T, Takasaki K, Oka M, Kameyama M, Toi M, Fujii H, Kitamura M, Murai M, Sasaki H, Ozono S, Makuuchi H, Shimada Y, Onishi Y, Aoyagi S, Mizutani K, Ogawa M, Nakao A, Kinoshita H, Tono T, Imamoto H, Nakashima Y, Manabe T: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 2000; 17:33-38.
15. Kobayashi N, Kubota T, Watanabe M, Otani Y, Teramoto T, Kitajima M: Pyrimidine nucleoside phosphorylase and dihydropyrimidine dehydrogenase indicate chemosensitivity of human colon cancer specimens to doxifluridine and 5-fluorouracil, respectively. J Infect Chemother 1999; 5:144-148.
16. Eda H, Fujimoto K, Watanabe S, Ura M, Hino A, Tanaka Y, Wada K, Ishitsuka H: Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993; 32:333-338.
17. Furukawa T, Yoshimura A, Sumizawa T, Haraguchi M, Akiyama S, Fukui K, Ishizawa M, Yamada Y: Angiogenic factor. Nature 1992; 356:668.
18. Sumizawa T, Furukawa T, Haraguchi M, Yoshimura A, Takeyasu A, Ishizawa M, Yamada Y, Akiyama S: Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J Biochem 1993; 114:9-14.
19. Haraguchi M, Miyadera K, Uemura K, Sumizawa T, Furukawa T, Yamada K, Akiyama S, Yamada Y: Angiogenic activity of enzymes. Nature 1994; 368:198.
20. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H, Tominaga T: Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer 1995; 64:79-82.
21. Osanai T, Ichikawa W, Takagi Y, Uetake H, Nihei Z, Sugihara K: Expression of pyrimidine nucleoside phosphorylase (PyNPase) in colorectal cancer. Jpn J Clin Oncol 2001; 31:500-505.
22. Nishimura G, Terada I, Kobayashi T, Ninomiya I, Kitagawa H, Fushida S, Fujimura T, Kayahara M, Shimizu K, Ohta T, Miwa K: Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy. Oncol Rep 2002; 9:479-482.
23. Weber G: Enzymology of cancer cells (first of two parts). New Eng J Med 1977; 296:486-493.
24. Tsuji T, Sawai T, Takeshita H, Nakagoe T, Hidaka S, Atsushi Nanashima, Yamaguchi H, Yasutake T, Nagayasu T, Tagawa Y: Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone. Cancer Lett 2004; 204:97-104.
25. Tsuji T, Sawai T, Takeshita H, Nakagoe T, Hidaka S, Yamaguchi H, Yasutake T, Nagayasu T, Tagawa Y: Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer. Cancer Chemother Pharmacol 2004; 54:531-536.
26. Kornmann M, Schwabe W, Sander S, Kron M, Strater J, Polat S, Kettner E, Weiser HF, Baumann W, Schramm H, Hausler P, Ott K, Behnke D, Staib L, Beger HG, Link KH: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003; 9:4116-4124.
27. Ichikawa W, Uetake H, Shirota Y, Yamada H, Nishi N, Nihei Z, Sugihara K, Hirayama R: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003; 9:786-791.